Sesquient is a drug owned by Lupin Inc. It is protected by 5 US drug patents filed in 2021 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 27, 2033. Details of Sesquient's patents and their expiration are given in the table below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | Active |
US9750822 | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | Active |
US9200088 | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | Active |
US8410077 | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | Active |
US7635773 | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Sesquient is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Sesquient's family patents as well as insights into ongoing legal events on those patents.
Sesquient's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Sesquient's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 27, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Sesquient Generics:
Fosphenytoin Sodium is the generic name for the brand Sesquient. 12 different companies have already filed for the generic of Sesquient, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Sesquient's generic
About Sesquient
Sesquient is a drug owned by Lupin Inc. Sesquient uses Fosphenytoin Sodium as an active ingredient. Sesquient was launched by Lupin in 2020.
Approval Date:
Sesquient was approved by FDA for market use on 05 November, 2020.
Active Ingredient:
Sesquient uses Fosphenytoin Sodium as the active ingredient. Check out other Drugs and Companies using Fosphenytoin Sodium ingredient
Dosage:
Sesquient is available in solution form for intravenous use. Given below is detailed information on Dosage -
Strength | Dosage Form | Availability | Application Pathway |
---|---|---|---|
EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML) | SOLUTION | Discontinued | INTRAVENOUS |
EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML) | SOLUTION | Discontinued | INTRAVENOUS |